New drug combo shows promise in slowing advanced breast cancer
NCT ID NCT01992952
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a targeted drug called AZD5363 to the standard hormone therapy fulvestrant can slow the growth of advanced estrogen-receptor-positive (ER+) breast cancer. It involves 149 postmenopausal women whose cancer has worsened despite prior treatment with an aromatase inhibitor. The trial has two phases: first finding the safest dose, then comparing the combination against fulvestrant alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD5363 (a targeted drug) combined with fulvestrant (a hormone therapy)
What this could lead to
If it works, this could offer a new treatment option that delays cancer progression for postmenopausal women with advanced ER+ breast cancer.
What could go wrong
This is an early-phase trial (1b/2) with a small number of participants, so results may not confirm benefit. The drug combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Blackpool Victoria Hospital
Blackpool, United Kingdom
-
Calderdale and Huddersfield NHS Foundation Trust
Huddersfield, United Kingdom
-
Christie Hospital
Manchester, Greater Manchester, United Kingdom
-
Clatterbridge Cancer Centre
Bebington, United Kingdom
-
Derriford Hospital
Plymouth, United Kingdom
-
Glan Clwyd Hospital
Rhyl, United Kingdom
-
Great Western General Hospital
Edinburgh, United Kingdom
-
Mount Vernon Cancer Centre
London, United Kingdom
-
Queen's Hospital
Romford, United Kingdom
-
Royal Albert and Edward Infirmary -Wrightington
Wigan, United Kingdom
-
Royal Blackburn Hospital
Blackburn, United Kingdom
-
Royal Free Hospital
London, United Kingdom
-
Royal Preston Hospital
Preston, United Kingdom
-
Royal Stoke University Hospital
Stoke-on-Trent, United Kingdom
-
Southampton General Hospital
Southampton, United Kingdom
-
St James's University Hospital
Leeds, United Kingdom
-
The Ipswich Hospital NHS Trust
Ipswich, United Kingdom
-
University Hospital of North Durham
Durham, United Kingdom
-
University Hospitals Morecambe Bay
Lancaster, United Kingdom
-
Velindre NHS Trust
Cardiff, Cardiff, United Kingdom
-
Ysbyty Gwynedd
Bangor, United Kingdom